Literature DB >> 24829396

A monotonic and prognostic genomic signature from fibroblasts for colorectal cancer initiation, progression, and metastasis.

Mireia Berdiel-Acer1, Daniel Cuadras2, Natalia Guillén Díaz-Maroto3, Xavier Sanjuan4, Teresa Serrano4, Antoni Berenguer5, Victor Moreno5, Samuel Gonçalves-Ribeiro3, Ramon Salazar6, Alberto Villanueva3, David G Molleví7.   

Abstract

UNLABELLED: The differential gene expression patterns between normal colonic fibroblasts (NCF), carcinoma-associated fibroblasts from primary tumors (CAF-PT), and CAFs from hepatic metastasis (CAF-LM) are hypothesized to be useful for predicting relapse in primary tumors. A transcriptomic profile of NCF (n = 9), CAF-PT (n = 14), and CAF-LM (n = 11) was derived. Prediction Analysis of Microarrays (PAM) was used to obtain molecular details for each fibroblast class, and differentially expressed transcripts were used to classify patients according to recurrence status. A number of transcripts (n = 277) were common to all three types of fibroblasts and whose expression level was sequentially deregulated according to the transition: NCF→CAF-PTCAF-LM. Importantly, the gene signature was able to accurately classify patients with primary tumors according to their prognosis. This capacity was exploited to obtain a refined 19-gene classifier that predicted recurrence with high accuracy in two independent datasets of patients with colorectal cancer and correlates with fibroblast migratory potential. The prognostic power of this genomic signature is strong evidence of the link between the tumor-stroma microenvironment and cancer progression. Furthermore, the 19-gene classifier was able to identify low-risk patients very accurately, which is of particular importance for stage II patients, who would benefit from the omission of chemotherapy, especially T4N0 patients, who are clinically classified as being at high risk. IMPLICATIONS: A defined stromal gene expression signature predicts relapse in patients with colorectal cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24829396     DOI: 10.1158/1541-7786.MCR-14-0121

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  14 in total

1.  Distinct Transcriptional Changes and Epithelial-Stromal Interactions Are Altered in Early-Stage Colon Cancer Development.

Authors:  Allen Mo; Stephen Jackson; Kamini Varma; Alan Carpino; Charles Giardina; Thomas J Devers; Daniel W Rosenberg
Journal:  Mol Cancer Res       Date:  2016-06-27       Impact factor: 5.852

2.  Comprehensive site-specific whole genome profiling of stromal and epithelial colonic gene signatures in human sigmoid colon and rectal tissue.

Authors:  Jason M Knight; Eunji Kim; Ivan Ivanov; Laurie A Davidson; Jennifer S Goldsby; Meredith A J Hullar; Timothy W Randolph; Andrew M Kaz; Lisa Levy; Johanna W Lampe; Robert S Chapkin
Journal:  Physiol Genomics       Date:  2016-07-08       Impact factor: 3.107

Review 3.  Cancer-associated fibroblasts in digestive tumors.

Authors:  Lei Huang; A-Man Xu; Sha Liu; Wei Liu; Tuan-Jie Li
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

4.  Colon fibroblasts from Pirc rats (F344/NTac-Apcam1137 ) exhibit a proliferative and inflammatory phenotype that could support early stages of colon carcinogenesis.

Authors:  Katia Tortora; Francesca Margheri; Cristina Luceri; Alessandra Mocali; Sara Ristori; Lucia Magnelli; Giovanna Caderni; Lisa Giovannelli
Journal:  Int J Cancer       Date:  2021-09-18       Impact factor: 7.316

Review 5.  Fibroblasts, an inconspicuous but essential player in colon cancer development and progression.

Authors:  Naofumi Mukaida; Soichiro Sasaki
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

6.  BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis.

Authors:  Quan Wan; Hayley Dingerdissen; Yu Fan; Naila Gulzar; Yang Pan; Tsung-Jung Wu; Cheng Yan; Haichen Zhang; Raja Mazumder
Journal:  Database (Oxford)       Date:  2015-03-28       Impact factor: 3.451

Review 7.  Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma.

Authors:  Zofia Felicja Bielecka; Anna Małgorzata Czarnecka; Cezary Szczylik
Journal:  Front Oncol       Date:  2014-07-25       Impact factor: 6.244

8.  MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.

Authors:  Zongyuan Yang; Sen Xu; Ping Jin; Xin Yang; Xiaoting Li; Dongyi Wan; Taoran Zhang; Sixiang Long; Xiao Wei; Gang Chen; Li Meng; Dan Liu; Yong Fang; Pingbo Chen; Ding Ma; Qinglei Gao
Journal:  Oncotarget       Date:  2016-06-21

9.  Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis.

Authors:  Rui Wei; Mengqin Lv; Fei Li; Teng Cheng; Zhengzhong Zhang; Guiying Jiang; Ying Zhou; Ruiqiu Gao; Xiao Wei; Jicheng Lou; Xizi Wu; Danfeng Luo; Xiangyi Ma; Jin Jiang; Ding Ma; Ling Xi
Journal:  Oncotarget       Date:  2017-06-27

10.  Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.

Authors:  Xiaoting Li; Zongyuan Yang; Sen Xu; Zhengzheng Wang; Ping Jin; Xin Yang; Zeyu Zhang; Ya Wang; Xiao Wei; Tian Fang; Qinglei Gao
Journal:  Dis Markers       Date:  2019-11-11       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.